Comparison of NODAT in Kidney Transplant Patients Receiving Belatacept Versus Standard Immunosuppression
Status:
Unknown status
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to determine if belatacept is an appropriate alternative
immunosuppressive medication (reducing the immune system's effect) when a kidney transplant
patient develops new onset diabetes after transplant (NODAT). Patients who are diagnosed with
NODAT will be approached with the opportunity to participate in this study. If they agree to
participate, they will be randomized one-to-one (like a coin flip) to the study arm
(belatacept) or the control arm (their current medication regimen). If a patient is
randomized to the study arm, they will be tapered off of their current regimen when they have
started receiving their monthly belatacept infusions. The control arm will mean the patient
will continue their current, standard of care medications, but following the tacrolimus
trough levels indicated within the study protocol. Different laboratory tests (i.e. fasting
blood glucose) will be measured during the study to monitor the progression of NODAT in all
patients.